AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Nov 06, 2013

New Survey Reveals More than Half of Americans are Living with Gastrointestinal Symptoms and Not Seeking Care from a Doctor

NORTH CHICAGO, Ill., Nov. 6, 2013 /PRNewswire/ -- According to a new, national survey of more than 2,000 U.S. adults, 72 percent said they have experienced at least one of the following gastrointestinal (GI) symptoms a few times a month or more: diarrhea, gas, bloating, stomach pain, frequent bowel movements, unexplained weight-loss and non-specific GI discomfort. Surprisingly, a majority of surveyed participants (74 percent) have lived with their GI symptoms for more than six months. Despite this, more than half (56 percent) of those who have experienced GI discomfort have not spoken with their primary care doctor because they do not believe their symptoms require physician attention.

Oct 25, 2013

AbbVie Reports Third-Quarter 2013 Financial Results

NORTH CHICAGO, Ill., Oct. 25, 2013 /PRNewswire/ --

Oct 24, 2013

AbbVie Named a Science Top Employer

NORTH CHICAGO, Ill., Oct. 24, 2013 /PRNewswire/ -- The journal Science named AbbVie as one of its 2013 Top Employers.  AbbVie ranked fourth in its first year on the annual list, as surveyed by more than 3,000 respondents.

Oct 03, 2013

AbbVie Presents Phase II Data Evaluating the Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease

NORTH CHICAGO, Ill., Oct. 3, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.1 Efficacy results were reported using a novel Hidradenitis Suppurativa Clinical Response (HiSCR) endpoint that was developed in consultation with regulatory health authorities. These data, which analyze the reduction of total abscess and inflammatory nodule (AN) count from baseline, were presented at the 22nd Congress of the European Dermatology and Venereology (EADV) meeting in Istanbul, Turkey.1 HUMIRA is not approved by health authorities for the treatment of HS.

Oct 01, 2013

AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting

NORTH CHICAGO, Ill., Oct. 1, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that new data from its phase II hepatitis C clinical development program will be presented at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C., November 1-5, 2013. In total, eight abstracts will be presented, four of which include additional analyses from the phase IIb AVIATOR study. The data examine sustained virologic response (SVR) concordance, patient adherence to the regimen, patient reported outcomes and the impact of ribavirin dose reduction.  

Sep 24, 2013

AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies

NORTH CHICAGO, Ill. and MECHELEN, Belgium, Sept. 24, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today that they have entered into a global alliance to discover, develop and commercialize novel potentiator and combination therapies in cystic fibrosis (CF), an inherited chronic disease that affects 70,000 people worldwide.

Sep 23, 2013

Ablynx And AbbVie Sign Global License Agreement For anti-IL-6R Nanobody, ALX-0061, To Treat Inflammatory Diseases

GHENT, Belgium and NORTH CHICAGO, Ill., Sept. 23, 2013 /PRNewswire/ -- Ablynx [Euronext Brussels: ABLX] and AbbVie [NYSE: ABBV] today announced that they have entered into a global license agreement to develop and commercialize the anti-IL-6R Nanobody, ALX-0061, to treat inflammatory diseases.  ALX-0061 is Ablynx's proprietary anti-IL-6R Nanobody that successfully completed a Phase IIa study in February 2013 reporting strong efficacy and safety data in patients with moderately to severely active rheumatoid arthritis (RA) on a stable background of methotrexate.

Aug 19, 2013

Vote to Help Award a $21,000 AbbVie CF Scholarship to Two Inspirational Students with Cystic Fibrosis Pursuing their Goals of Higher Education

NORTH CHICAGO, Ill., Aug. 19, 2013 /PRNewswire/ -- AbbVie has selected 40 exceptional undergraduate and graduate students living with cystic fibrosis (CF) to each receive a $2,500 AbbVie CF Scholarship for the 2013-2014 school year based on their academic excellence, extracurricular activities and creativity. The AbbVie CF Scholars are now competing for two additional scholarships for a total award of $21,000 each and the title of 2013 Thriving Undergraduate or Graduate Student. From now until Monday, Sept. 16, 2013, please vote at www.AbbVieCFScholarship.com for two outstanding and inspirational scholars.

Jul 26, 2013

AbbVie Reports Second-Quarter 2013 Financial Results

NORTH CHICAGO, Ill., July 26, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced financial results for the second quarter ended June 30, 2013.

Jul 08, 2013

Stacy London Launches Uncover Your Confidence™ Campaign to Empower People Living with Psoriasis

NORTH CHICAGO, Ill., July 8, 2013 /PRNewswire/ -- Stacy London, style expert and co-host of TLC's "What Not to Wear," today announced her partnership with AbbVie (NYSE: ABBV) on a new psoriasis campaign called Uncover Your Confidence. The campaign features educational resources and style advice for the estimated 7.5 million American men and women living with psoriasis.[1] Commonly mistaken as "just a skin condition," psoriasis is actually a chronic disease of the immune system that appears on the skin.